RESUMEN
Crotamiton (CRT) is a commonly approved drug prescribed for the scabies treatment in many countries across the globe. However, poor aqueous solubility and low bioavailability, and side effects restrict its use. To avoid such issues, an appropriate carrier system is necessary which can address the aforementioned challenges for attaining enhanced biopharmaceutical attributes. The current study intends to provide a detailed account on the development and evaluation of CRT-loaded microemulsion (ME) hydrogel formulation containing tea tree oil (TTO) for improved drug delivery for scabies treatment in a safe and effective manner. Pseudo-ternary phase diagrams were constructed with TTO as the oily phase, and Cremophor®EL was used as the surfactant in a mass ratio 2:1 with co-surfactants (mixture of phospholipid 90G and Transcutol®P), and aqueous solution as the external phase. The optimized drug-loaded ME formulation was evaluated for skin penetration, retention, compliance, and dermatokinetics. The nonirritant behavior of the formulation was revealed by skin histopathology, which showed no changes in normal skin histology. In comparison to the conventional product, dermatokinetic experiments revealed that CRT has greater penetration and distribution in the epidermis of the mice skin. The findings imply that the proposed lipid-based ME hydrogel can aid in the resolution of CRT issues by providing a better and safer delivery option to epidermis and deeper epidermis in substantial quantities.
Asunto(s)
Emulsiones/química , Hidrogeles/química , Escabiosis/tratamiento farmacológico , Aceite de Árbol de Té/química , Toluidinas/farmacocinética , Animales , Química Farmacéutica , Portadores de Fármacos , Estabilidad de Medicamentos , Concentración de Iones de Hidrógeno , Ratones , Propiedades de Superficie , Tensoactivos/química , Toluidinas/administración & dosificaciónRESUMEN
Rheumatoid arthritis (RA), an autoimmune inflammatory disorder is currently incurable. Methotrexate and Teriflunomide are routinely prescribed drugs but their uses are limited due to severe hepatotoxicity. Hyaluronic acid (HYA) is a targeting ligand for CD44 receptors overexpressed on inflamed macrophages. The present investigation aimed at design and fabrication of HYA coated hydroxyapatite nanoparticles (HA-NPs) loaded with Methotrexate (MTX) and Teriflunomide (TEF) (HAMT-NPs) to form HYA-HAMT-NPs for the treatment of RA. HYA-HAMT-NPs showed the nanoscale size of 274.9 ± 64 nm along with a zeta potential value of -26.80 ± 6.08 mV. FTIR spectra of HYA and HYA-HAMT-NPs proved the coating of HYA on HYA-HAMT-NPs. HYA-HAMT-NPs showed less cell viability compared to drugs on RAW 264.7 macrophage cells. A biodistribution study by gamma scintigraphy imaging further strengthened the results by revealing significantly higher (p<0.05) percentage radioactivity (76.76%) of HYA-HAMT-NPs in the synovial region. The results obtained by pharmacodynamic studies ensured the better efficacy of HYA-HAMT-NPs in preventing disease progression and promoting articular regeneration. Under hepatotoxicity evaluation, liver histopathology and liver enzyme assay revealed ~29% hepatotoxicity was reduced by HYA-HAMT-NPs when compared to conventional FOLITRAX-10 and AUBAGIO oral treatments. Overall, the results suggest that HYA-HAMT-NP is a promising delivery system to avoid drug-induced hepatotoxicity in RA.
Asunto(s)
Antirreumáticos/administración & dosificación , Artritis Experimental/tratamiento farmacológico , Artritis Reumatoide/tratamiento farmacológico , Crotonatos/administración & dosificación , Portadores de Fármacos/administración & dosificación , Durapatita/química , Ácido Hialurónico/química , Metotrexato/administración & dosificación , Nanopartículas/administración & dosificación , Toluidinas/administración & dosificación , Animales , Antirreumáticos/farmacocinética , Antirreumáticos/uso terapéutico , Antirreumáticos/toxicidad , Artritis Experimental/patología , Crotonatos/farmacocinética , Crotonatos/uso terapéutico , Crotonatos/toxicidad , Citocinas/sangre , Portadores de Fármacos/farmacocinética , Portadores de Fármacos/toxicidad , Evaluación Preclínica de Medicamentos , Liberación de Fármacos , Hidroxibutiratos , Hígado/efectos de los fármacos , Hígado/enzimología , Hígado/patología , Metotrexato/farmacocinética , Metotrexato/uso terapéutico , Metotrexato/toxicidad , Ratones , Nanopartículas/toxicidad , Nitrilos , Células RAW 264.7 , Ratas , Ratas Wistar , Espectroscopía Infrarroja por Transformada de Fourier , Distribución Tisular , Toluidinas/farmacocinética , Toluidinas/uso terapéutico , Toluidinas/toxicidadRESUMEN
OBJECTIVE: Leflunomide is a commonly used disease-modifying drug in the treatment of rheumatoid arthritis (RA). Its effects are mediated via inhibition of dihydroorotate dehydrogenase (DHODH) by its active metabolite teriflunomide, and the pharmacokinetics of teriflunomide are highly variable. Our objective was to examine the association between the DHODH haplotype and plasma teriflunomide concentration with response to leflunomide in patients with RA where leflunomide was added to an existing disease-modifying drug regimen after failure to achieve an adequate response with conventional triple therapy. METHODS: Patients with RA who were taking, or were about to initiate, leflunomide were included. Participant characteristics, including the DHODH haplotype, were determined. Up to 5 plasma samples were collected after leflunomide was initiated for assays of total and free teriflunomide concentration. Disease activity was determined via the 28-joint Disease Activity Score (DAS28). The association between DAS28 scores and patient covariates was determined by linear mixed-effects modeling. RESULTS: A total of 67 patients were included in the study. The DAS28 score after initiation of leflunomide was associated with the baseline DAS28 score (ß = 0.70, P < 0.001) and was higher in those who carried the DHODH haplotype 2 (ß = 0.56. P = 0.01) and did not carry the shared epitope (ß = 0.56, P = 0.013). As total and free plasma teriflunomide concentration increased, the DAS28 score was significantly lower (P < 0.001 and P = 0.001, respectively). When considering threshold concentrations, teriflunomide concentrations >16 mg/liter were associated with a DAS28 score that was 0.33 lower, and when free teriflunomide concentration was >35 µg/liter, the DAS28 score was 0.32 lower. CONCLUSION: Teriflunomide concentration and carriage of the DHODH haplotype 2 are associated with response to leflunomide in patients with RA, and a total plasma teriflunomide concentration of at least 16 mg/liter is needed to maximize the likelihood of response.
Asunto(s)
Artritis Reumatoide/tratamiento farmacológico , Crotonatos/farmacocinética , Inhibidores Enzimáticos/farmacocinética , Hidroxibutiratos/farmacocinética , Inmunosupresores/farmacocinética , Leflunamida/farmacocinética , Nitrilos/farmacocinética , Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH/antagonistas & inhibidores , Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH/genética , Variantes Farmacogenómicas , Polimorfismo de Nucleótido Simple , Toluidinas/farmacocinética , Adulto , Artritis Reumatoide/diagnóstico , Artritis Reumatoide/genética , Crotonatos/sangre , Dihidroorotato Deshidrogenasa , Monitoreo de Drogas , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/sangre , Femenino , Haplotipos , Humanos , Hidroxibutiratos/sangre , Inmunosupresores/administración & dosificación , Inmunosupresores/sangre , Leflunamida/administración & dosificación , Leflunamida/sangre , Masculino , Persona de Mediana Edad , Nitrilos/sangre , Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH/metabolismo , Farmacogenética , Medicina de Precisión , Recuperación de la Función , Inducción de Remisión , Toluidinas/sangre , Resultado del TratamientoRESUMEN
This research aims to coat Teriflunomide (TEF) loaded conventional nanoliposomes (CON-TEF-LIPO) with Chondroitin sulphate (CS) to produce CS-TEF-LIPO for the effective treatment of Rheumatoid arthritis (RA). Both CON-TEF-LIPO and CS-TEF-LIPO were produced, characterized and evaluated for their active targeting potential towards CD44 receptors. Cell cytotoxicity, cell viability and intracellular uptake study on differentiated U937 and MG-63 cells demonstrated the active targeting of CS-TEF-LIPO towards CD44 receptors. Furthermore, in vivo pharmacodynamic, biochemical, radiological and histopathological studies performed in adjuvant induced arthritic (AIA) rat model showed a significant (P < 0.05) reduction in inflammation in arthritic rat paw in CS-TEF-LIPO group compared to TEF and CON-TEF-LIPO groups. Moreover, liver toxicity study revealed that CS-TEF-LIPO showed no signs of toxicity and biodistribution study revealed the accumulation of CS-TEF-LIPO in synovial region of arthritic rat. Taken together, results suggest that CS-TEF-LIPO could provide a new insight for an effective treatment of RA.
Asunto(s)
Artritis Experimental/tratamiento farmacológico , Artritis Reumatoide/tratamiento farmacológico , Sulfatos de Condroitina/química , Crotonatos/farmacología , Glioma/tratamiento farmacológico , Liposomas/administración & dosificación , Nanopartículas/administración & dosificación , Toluidinas/farmacología , Animales , Artritis Experimental/patología , Artritis Reumatoide/patología , Crotonatos/farmacocinética , Glioma/patología , Humanos , Hidroxibutiratos , Liposomas/química , Masculino , Nanopartículas/química , Nitrilos , Ratas , Ratas Wistar , Distribución Tisular , Toluidinas/farmacocinética , Células Tumorales CultivadasRESUMEN
Teriflunomide is an oral first-line disease modifying treatment (DMT) for patients with relapsing-remitting multiple sclerosis (RRMS). It can take up to two years to achieve systemic clearance of teriflunomide to an acceptable level, but this washout period may be accelerated by administration of cholestyramine. Relapse of multiple sclerosis (MS) during washout of teriflunomide or other first-line DMT is not as common. We report two patients with RRMS who experienced a relapse after the accelerated elimination period (AEP) of teriflunomide and confirmation of negative plasmatic levels (<0.02 µg/ml). In cases of risk of MS activity, we should not wait for teriflunomide negative plasmatic levels confirmation before starting the next DMT to reduce the risk of relapse.
Asunto(s)
Crotonatos/farmacocinética , Factores Inmunológicos/farmacocinética , Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico , Esclerosis Múltiple Recurrente-Remitente/fisiopatología , Toluidinas/farmacocinética , Adulto , Resinas de Intercambio Aniónico/administración & dosificación , Resina de Colestiramina/administración & dosificación , Crotonatos/sangre , Femenino , Humanos , Hidroxibutiratos , Factores Inmunológicos/sangre , Masculino , Nitrilos , Recurrencia , Toluidinas/sangreRESUMEN
Tolylfluanid (TF) is a sensitizing biocide used in antifouling products and wood preservatives. Paint application is associated with skin exposure; however, the importance of this exposure route is uncertain as TF skin permeation rates are lacking in the peer-reviewed scientific literature. TF is a lipophilic powder that hydrolyses rapidly in contact with water to dimethylamino sulfotoluidid (DMST). DMST is also a TF metabolite. We characterized TF and DMST skin permeation using an ex vivo flow-through diffusion system with viable and frozen human skin. TF permeated as DMST with a low permeation rate (0.18 ± 0.05 µg/cm2/h) and a moderate time lag (7.1 ± 1.4 h) in viable human skin. Applying DMST gave a 3.5-fold lower permeation rate (0.05 ± 0.01 µg/cm2/h) compared to TF under a similar experimental setting. We simulated paint activities in an exposure chamber to understand a possible skin exposure from airborne TF concentrations. Although, paint can deposit onto the skin during work activities, TF permeation when paint was applied to human skin ex vivo was very low (as TF: 0.004 ± 0.005 µg/cm2/h, and as DMST: 0.02 ± 0.001 µg/cm2/h). Our results show that TF can permeate skin, and consequently, can contribute to sensitization, which support previous reports on sensitization in TF exposed workers.
Asunto(s)
Piel/metabolismo , Sulfonamidas/farmacocinética , Toluidinas/farmacocinética , Contaminantes Atmosféricos/análisis , Humanos , Hidrólisis , Exposición Profesional , Pintura , Permeabilidad , Solubilidad , Sulfonamidas/análisis , Sulfonamidas/química , Toluidinas/análisis , Toluidinas/químicaRESUMEN
Multiple sclerosis, which is characterized by inflammation and neurodegeneration, is considered a chronic disease of the central nervous system. Given the lack of pharmacokinetic evaluation of teriflunomide in the Iranian context, the present 2-way crossover study aimed to assess the pharmacokinetic properties and bioequivalence of 2 teriflunomide formulations. To this end, 2 single-dose generic and branded teriflunomide formulations were orally administered to 14 healthy Iranian male volunteers. A washout period of 21 days was allowed between the treatments. The plasma samples containing teriflunomide were analyzed by a simple and sensitive high-performance liquid chromatography method using standard ultraviolet detection. In addition, the pharmacokinetic parameters were calculated for bioequivalence evaluation. The peak area ratio between the teriflunomide and the internal standard was the source of calibration curves, which were linear over the range of 20-40,000 ng/mL (R2 = 0.9994). The results indicated that the 2 formulations had similar pharmacokinetics. Further, the 90%CI of the mean ratios of the test versus the reference formulations of log-transformed area under the concentration-time curve over 72 hours (93% to 107%) and peak concentration (92% to 108%) were within the acceptable range of 80% to 125%. Based on the obtained results, the test formulation of teriflunomide could be similar to that of the reference formulation.
Asunto(s)
Crotonatos/administración & dosificación , Medicamentos Genéricos/administración & dosificación , Toluidinas/administración & dosificación , Administración Oral , Adulto , Área Bajo la Curva , Cromatografía Líquida de Alta Presión , Estudios Cruzados , Crotonatos/farmacocinética , Medicamentos Genéricos/farmacocinética , Humanos , Hidroxibutiratos , Irán , Masculino , Persona de Mediana Edad , Nitrilos , Equivalencia Terapéutica , Toluidinas/farmacocinética , Adulto JovenRESUMEN
The aim of the present work was to develop compound transdermal patch containing teriflunomide (TEF) and ketoprofen (KTP) using permeation enhancement strategy; reveal the molecular mechanism by which Azone (AZ) promoted transdermal absorption of compound patch through the enhancement of drug-drug intermolecular interaction. The formulation was optimized using in vitro skin permeation study and confirmed with pharmacodynamics study, anti-inflammatory study and analgesics study. Enhanced drug-drug interaction by AZ was characterized using FT-IR, 13C NMR, molecular modeling and thermal analysis. The optimized formulation was composed of TEF (3%), KTP (2%), AZ (10%) and DURO-TAK® 87-4098 as adhesive matrix. The skin permeation amount of TEF-KTP combination was promoted by AZ about 1.9 times (594.2⯱â¯46.8⯵g/cm2) and 1.2 times (502.92⯱â¯24.0⯵g/cm2) compared with TEF-AZ and KTP-AZ individual patch. It was proved that the interaction between TEF and KTP via hydrogen bonding was further enhanced by AZ due to the increased molecular mobility of acrylate polymer (ΔTgâ¯=â¯-17.7⯰C), which was proved by FTIR and 13C NMR spectra. The enhanced drug-drug intermolecular interaction increased drug dispersed status and decreased the quantity of drug's hydrogen bonding site, thus increasing the drug release amount significantly. In conclusion, a compound transdermal patch containing KTP and TEF was developed successfully and a novel enhancement mechanism was clarified at molecular level, which provided reference for the development of novel compound transdermal patch.
Asunto(s)
Analgésicos/administración & dosificación , Antiinflamatorios no Esteroideos/administración & dosificación , Artritis Experimental/prevención & control , Azepinas/administración & dosificación , Crotonatos/administración & dosificación , Cetoprofeno/administración & dosificación , Dolor/prevención & control , Absorción Cutánea/efectos de los fármacos , Toluidinas/administración & dosificación , Parche Transdérmico , Ácido Acético , Administración Cutánea , Analgésicos/química , Analgésicos/farmacocinética , Animales , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/farmacocinética , Artritis Experimental/inducido químicamente , Azepinas/química , Crotonatos/química , Crotonatos/farmacocinética , Combinación de Medicamentos , Composición de Medicamentos , Interacciones Farmacológicas , Liberación de Fármacos , Adyuvante de Freund , Enlace de Hidrógeno , Hidroxibutiratos , Cetoprofeno/química , Cetoprofeno/farmacocinética , Masculino , Ratones , Nitrilos , Dolor/inducido químicamente , Permeabilidad , Conejos , Ratas , Toluidinas/química , Toluidinas/farmacocinéticaRESUMEN
PURPOSE: To accelerate early phase clinical development of a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus (SLE) based on the data of leflunomide. METHODS: Based on a pharmacokinetic (PK) study assessing the relative bioavailability of teriflunomide sodium compared to leflunomide, a population pharmacokinetic (Pop PK) analysis was firstly conducted using non-linear mixed effect model. Covariates were thoughtfully screened after Pop PK model evaluation and qualification using various diagnostic plots, visual predicted check (VPC) and bootstrap method. In order to predict teriflunomide PK profiles for multiple dosing of teriflunomide sodium in SLE patients, a model integrating enterohepatic circulation (EHC) mechanism was utilized to simulate the teriflunomide PK profile after multiple dosing of 20â¯mg/day leflunomide, and compare it to the teriflunomide PK profile in a 20â¯mg/day leflunomide multiple dose study in rheumatoid arthritis patients. Validated EHC PK model was applied to optimize dose regimen for teriflunomide sodium in SLE patients. RESULTS: A population one-compartment model with pulsed EHC characteristic was developed to capture teriflunomide PK profiles after administration of leflunomide and teriflunomide sodium. Body weight and male sex were found to significantly increase apparent volume of central compartment. ABCG2 34G>A polymorphism was found to significantly change apparent clearance and absorption rate. The Pop PK model was evaluated and validated. After this model was confirmed to capture EHC characteristics of teriflunomide in both healthy subjects and patients with rheumatoid arthritis after single and multiple dosing leflunomide, it was applied to suggest dose regimen of teriflunomide sodium in phase II study. CONCLUSIONS: The pulsed EHC Pop PK model characterized the teriflunomide PK processes well in both healthy subjects and patients. Body weight, sex, and ABCG2 34G>A genotype were identified to significantly affect PK characteristics. The developed EHC Pop PK model exhibited the ability to predict PK profiles of teriflunomide in patients after long-term dosing and could be utilized to support phase II trial design.
Asunto(s)
Crotonatos/farmacocinética , Crotonatos/uso terapéutico , Lupus Eritematoso Sistémico/tratamiento farmacológico , Sodio/farmacocinética , Toluidinas/farmacocinética , Toluidinas/uso terapéutico , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2/genética , Artritis Reumatoide/tratamiento farmacológico , Artritis Reumatoide/genética , Artritis Reumatoide/metabolismo , Peso Corporal/efectos de los fármacos , Femenino , Humanos , Hidroxibutiratos , Leflunamida/uso terapéutico , Lupus Eritematoso Sistémico/genética , Lupus Eritematoso Sistémico/metabolismo , Masculino , Persona de Mediana Edad , Modelos Biológicos , NitrilosRESUMEN
BACKGROUND: Teriflunomide sodium, a novel derivative of leflunomide, was developed to treat systemic lupus erythematosus. OBJECTIVE: The objectives of this trial were to study the safety, pharmacokinetics, and pharmacogenetics of teriflunomide sodium in healthy Chinese subjects in order to support its accelerated development. METHODS: A clinical study was designed as a single-dose, randomized, parallel, open-label study. Healthy volunteers were randomly assigned to take teriflunomide sodium 10 mg or leflunomide 10 mg. Eligible healthy volunteers were monitored over a 98-day observation period. Blood and urine samples were collected and analyzed for teriflunomide and its metabolite concentrations, and ABCG2 and CYP2C9 genotypes were detected. The safety profile was also collected. RESULTS: All adverse events were mild in intensity, and all subjects completed this trial without any other treatment. After a single administration of teriflunomide sodium and leflunomide, teriflunomide maximal concentrations were 1.32 ± 0.341 mg/L and 0.718 ± 0.169 mg/L, and area under the concentration-time curve from time zero to infinity (AUC∞) was 423 ± 229 mg·h/L and 303 ± 159 mg·h/L, respectively. Overall, teriflunomide AUC∞ in ABCG2 34A/A mutants was 70.4% lower than in wild-type ABCG2 34G/G after administration of teriflunomide sodium. In addition, after administration of leflunomide, teriflunomide AUC∞ in ABCG2 34A/A mutants was 30.0% lower than in subjects carrying ABCG2 34G/G. CONCLUSIONS: Teriflunomide sodium was generally safe and well tolerated in healthy Chinese subjects. The relative bioavailability of teriflunomide between teriflunomide sodium and leflunomide after a single dose administration was approximately 150%. Additionally, ABCG2 34G>A was found to significantly affect teriflunomide pharmacokinetics, which suggested ABCG2 34G>A may be a significant influencing factor. CLINICAL TRIAL REGISTRATION: This study was registered at the China National Medical Products Administration ( http://www.nmpa.gov.cn ; registration number 2014L01935), and also at the China platform for registry and publicity of drug clinical trials ( http://www.chinadrugtrials.org.cn ; registration number CTR20150314).
Asunto(s)
Crotonatos/farmacocinética , Leflunamida/farmacocinética , Farmacogenética , Toluidinas/farmacocinética , Adulto , Anciano , Área Bajo la Curva , Pueblo Asiatico , China , Estudios Cruzados , Crotonatos/efectos adversos , Femenino , Genotipo , Humanos , Hidroxibutiratos , Lactancia , Leflunamida/efectos adversos , Masculino , Persona de Mediana Edad , Nitrilos , Polimorfismo de Nucleótido Simple , Toluidinas/efectos adversos , Adulto JovenRESUMEN
BACKGROUND: Multiple sclerosis (MS) is one of the most severe autoimmune disorder of the central nervous system (CNS). OBJECTIVE: The present research work was aimed to formulate and investigate teriflunomide (TFM)-loaded intranasal (i.n.) nanostructured lipid carriers (NLC) for the treatment of multiple sclerosis (MS). METHODS: The TFM-loaded NLC (TFM-NLC) nanoparticles were prepared by melt emulsification ultrasonication method using biodegradable and biocompatible polymers. The Box-Behnken statistical design was applied to optimize the formulation. The optimized NLC formulation was subjected to evaluate for particle size, entrapment efficiency (%), in vitro and ex vivo permeation. The safety and efficacy of optimized formulations were demonstrated using pharmacodynamic, subacute toxicity and hepatotoxicity data. RESULTS: Experimental data demonstrated that optimized NLC formulation (F17) showed significant size (99.82 ± 1.36 nm), zeta potential (-22.29 ± 1.8 mV) and % entrapment efficiency (83.39 ± 1.24%). Alternatively, ex vivo permeation of TFM mucoadhesive NLC (TFM-MNLC) and TFM-NLC was observed 830 ± 7.6 and 651 ± 9.8 µg/cm2, respectively. Whereas, TFM-MNLC shows around 2.0-folds more Jss than the TFM-NLC. Finally, TFM-MNLC (i.n.) formulation produced the rapid remyelination in cuprizone-treated animals and decreases the number of entries in open compartment of EPM when compared with negative control and TFM-NLC (oral) animals. Simultaneously, the nanoformulation did not reflect any gross changes in hepatic biomarkers and subacute toxicity when compared with control. CONCLUSIONS: Hence it can be inferred that the nose-to-brain delivery of TFM-MNLC can be considered as effective and safe delivery for brain disorders.
Asunto(s)
Crotonatos/administración & dosificación , Portadores de Fármacos/química , Esclerosis Múltiple/tratamiento farmacológico , Toluidinas/administración & dosificación , Adhesividad , Administración Intranasal , Administración Oral , Animales , Materiales Biocompatibles/química , Biomarcadores/metabolismo , Crotonatos/farmacocinética , Cuprizona/toxicidad , Modelos Animales de Enfermedad , Liberación de Fármacos , Humanos , Hidroxibutiratos , Lípidos/química , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Esclerosis Múltiple/inducido químicamente , Nanopartículas/química , Mucosa Nasal/metabolismo , Nitrilos , Tamaño de la Partícula , Polímeros/química , Ratas , Ratas Wistar , Ovinos , Toluidinas/farmacocinética , Pruebas de Toxicidad SubagudaRESUMEN
Amitraz is an acaricide and insecticide widely used in agriculture and veterinary medicine. Although central nervous system (CNS) toxicity is one of major toxicities following oral ingestion of amitraz, the understanding of the cause of the toxicity is limited. This study evaluated the systemic and brain exposure of amitraz and its major metabolites, BTS27271, 2',4'-formoxylidide, and 2,4-dimethylaniline following administration of amitraz in male Sprague-Dawley rats. Significant metabolism of amitraz was observed following the intravenous and oral administration. Amitraz related metabolites were majority of the total exposure observed, especially following oral administration. BTS27271 had higher brain exposure than amitraz and its other metabolites, which was due to low plasma protein binding but high brain tissue binding of BTS27271. Since BTS27271 has similar or higher toxicity and α2-adrenoreceptor agonist potency than amitraz, its exposure in brain tissues may be the major cause of CNS toxicity of amitraz in animals and humans.
Asunto(s)
Acaricidas/farmacocinética , Encéfalo/metabolismo , Insecticidas/farmacocinética , Toluidinas/farmacocinética , Administración Intravenosa , Administración Oral , Agonistas de Receptores Adrenérgicos alfa 2/metabolismo , Amidinas/metabolismo , Animales , Masculino , Ratas Sprague-DawleyRESUMEN
Leflunomide is a prodrug that is metabolized to the active metabolite, teriflunomide (A77 1726), to inhibit the enzyme dihydroorotate dehydrogenase and decrease the synthesis of pyrimidine nucleotides for DNA and RNA synthesis. Teriflunomide is primarily used for the treatment of rheumatoid arthritis and multiple sclerosis.A liquid chromatography tandem mass spectrometry (LC-MS/MS) method was developed and validated to quantify the drug teriflunomide over a concentration range of 5 ng/mL-200 µg/mL in serum or plasma. The calibration curve was divided into two separate overlapping regions of the analytical measurement range, with a high curve and a low curve range. Samples are first analyzed using the high-range calibration curve after a 100-fold dilution of the sample extract. Samples falling below the upper curve region are evaluated again without dilution and quantified, if possible, against the low curve calibration standards. This method can be used to support therapeutic drug monitoring of patients that are administered with leflunomide therapy.
Asunto(s)
Cromatografía Liquida , Crotonatos/farmacocinética , Inmunosupresores/farmacocinética , Leflunamida/farmacocinética , Espectrometría de Masas en Tándem , Toluidinas/farmacocinética , Crotonatos/química , Humanos , Hidroxibutiratos , Leflunamida/química , Estructura Molecular , Nitrilos , Toluidinas/químicaRESUMEN
A simple high-performance liquid chromatography coupled with tandem mass spectrometry method was developed and fully validated to simultaneously determine teriflunomide (TER) and its metabolite 4-trifluoro-methylaniline oxanilic acid (4-TMOA) in human plasma and urine. Merely 50 µL plasma and 20 µL urine were employed in sample preparation using protein precipitation and direct dilution method, respectively. An Agilent Zorbax eclipse plus C18 column was selected to achieve rapid separation for TER and 4-TMOA within 3 min. Electrospray ionization under multiple reaction monitoring was used to monitor the ion transitions for TER (m/z 269.0 â 159.9), 4-TMOA (m/z 231.9 â 160.0), internal standard teriflunomide-d4 (m/z 273.0 â 164.0) and 2-amino-4-trifluoromethyl benzoic acid (m/z 203.8 â 120.1), operating in the negative ion mode. This method proved to have better accuracy and precision over concentration range of 10-5000 ng/mL in plasma as well as 10-10,000 ng/mL in urine. After a full validation, this method was successfully applied in a pharmacokinetic study of teriflunomide sodium and leflunomide in Chinese healthy volunteers.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Crotonatos/sangre , Crotonatos/orina , Leflunamida/sangre , Leflunamida/orina , Espectrometría de Masas en Tándem/métodos , Toluidinas/sangre , Toluidinas/orina , Crotonatos/química , Crotonatos/farmacocinética , Estabilidad de Medicamentos , Humanos , Hidroxibutiratos , Leflunamida/química , Leflunamida/farmacocinética , Límite de Detección , Modelos Lineales , Nitrilos , Reproducibilidad de los Resultados , Toluidinas/química , Toluidinas/farmacocinéticaRESUMEN
The avicide 3chloro4methylanaline hydrochloride (chloroptoluidine hydrochloride, CPTH, DRC-1339) is used to control pest bird species that damage agricultural crops. A specific and sensitive gas chromatography-tandem mass spectrometry method was developed and validated for the determination of CPTH in avian breast muscle, GI tract, kidney, and liver. Tissue samples were extracted with a solution of acidified water and acetonitrile. The sample was made basic and cleaned up with a combination of liquid-liquid partitioning and solid phase extraction. Separation was achieved using a HP-5 ultra-inert GC column (15â¯M, 0.25⯵m film) with detection on a triple quadrupole mass spectrometer in multiple reaction monitoring (MRM) mode. The monitored transition for CPTH was m/z 140.9â¯ââ¯106.2 for quantitation and 139.9â¯ââ¯105.2 and 139.9â¯ââ¯77.2 for confirmation. The linear range was 5 to 5000â¯ng/mL. The precision for the determination of CPTH in all tissues averaged 7.2% and the accuracy averaged 6.7%. The recovery of CPTH fortified at 5 different levels averaged 101% in liver, 98.8% in GI tract, 92.9% in breast muscle, and 87.9% in kidney. The established method was successfully used to determine CPTH residue levels in red-winged blackbirds exposed to three different doses of CPTH.
Asunto(s)
Residuos de Medicamentos/análisis , Cromatografía de Gases y Espectrometría de Masas/métodos , Passeriformes , Espectrometría de Masas en Tándem/métodos , Toluidinas/análisis , Animales , Límite de Detección , Modelos Lineales , Reproducibilidad de los Resultados , Distribución Tisular , Toluidinas/farmacocinéticaRESUMEN
PURPOSE: The present investigation was aimed at developing Teriflunomide (TEF) and Methotrexate (MTX) loaded hydroxyapatite nanoparticles and increasing tolerability towards combination therapy against rheumatoid arthritis by reducing hepatotoxicity. METHODS: Drug-loaded HAp-NPs were synthesized by wet-chemical precipitation method and optimized by Box-Behnken experimental design. The developed NPs were subjected to in vitro and in vivo characterization. In-vivo pharmacodynamics and biochemical studies were performed on adjuvant- induced arthritis model treated with different formulations; MTX-TEF-SOL, TEF-HAp-NP, MTX-HAp-NP, TEF-MTX-HAp-NP, FOLITRAX-10 and AUBAGIO. RESULTS: The size of the optimized formulations, TEF-HAp-NP and MTX-HAp-NP, was found to be 224.3 ± 83.80 nm and 268.3 ± 73.86 nm with drug loading 53.11 ± 0.84% and 67.04 ± 1.12% respectively. In vitro release of TEF from TEF-HAp-NP (70.41 ± 1.22%) and MTX from MTX-HAp-NP (82.43 ± 1.31%) up to 24 h revealed sustained release pattern. Results of the arthritic assessment study showed a significant (P < 0.05) reduction in ankle diameter (61.30 ± 7.42) and arthritis score (2.35 ± 0.24) with a marked restoration of ankle joint micro-architecture in TEF-MTX-HAp-NP treated group. During Hepatotoxicity studies, liver histopathology revealed that the formulation MTX-TEF-HAp-NP was least hepatotoxic with less hepatocyte swelling and fibrous connective tissue proliferation while Folitrax-10 was found to be most hepatotoxic. Biochemical studies revealed that Folitrax-10 significantly (P < 0.05) increased the GOT (313.64 ± 16) and GPT level (334.46 ± 13) while insignificant (P > 0.05) change in GOT (263.68 ± 17) and GPT (229.38 ± 10) level was recorded with TEF-MTX-HAp-NP. CONCLUSIONS: We report that the subcutaneous delivery of TEF-MTX-HAp-NP was most effective as it successfully reduced the dosage by half for maximizing therapeutic efficacy and minimizing side effects. Graphical Abstract á .
Asunto(s)
Antirreumáticos/administración & dosificación , Artritis Experimental/tratamiento farmacológico , Artritis Reumatoide/tratamiento farmacológico , Crotonatos/administración & dosificación , Durapatita/química , Metotrexato/administración & dosificación , Nanopartículas/química , Toluidinas/administración & dosificación , Animales , Antirreumáticos/farmacocinética , Antirreumáticos/farmacología , Artritis Experimental/patología , Artritis Reumatoide/patología , Crotonatos/farmacocinética , Crotonatos/farmacología , Portadores de Fármacos , Combinación de Medicamentos , Composición de Medicamentos , Liberación de Fármacos , Estabilidad de Medicamentos , Femenino , Concentración de Iones de Hidrógeno , Hidroxibutiratos , Cinética , Metotrexato/farmacocinética , Metotrexato/farmacología , Nitrilos , Estrés Oxidativo/efectos de los fármacos , Tamaño de la Partícula , Ratas , Ratas Wistar , Distribución Tisular , Toluidinas/farmacocinética , Toluidinas/farmacologíaRESUMEN
Breast cancer resistance protein (BCRP) is a point of interest in drug-drug interaction safety testing. Therefore, a consensus probe that can be applied as victim in multiple experimental settings is of great benefit. Identification of candidates has been driven by the amount and quality of available clinical data, and as a result, drugs such as sulfasalazine and rosuvastatin have been suggested. In this article, the in vitro performance of 5 possible alternatives was evaluated: atorvastatin, chlorothiazide, dantrolene, topotecan, and teriflunomide, and benchmarked against sulfasalazine and rosuvastatin in reference in vitro assays for BCRP drug-drug interaction testing. Based on the results, teriflunomide is proposed as an alternate in vitro BCRP probe.
Asunto(s)
Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2/metabolismo , Proteínas de Neoplasias/metabolismo , Animales , Transporte Biológico , Células CACO-2 , Crotonatos/metabolismo , Crotonatos/farmacocinética , Crotonatos/farmacología , Perros , Interacciones Farmacológicas , Humanos , Hidroxibutiratos , Células de Riñón Canino Madin Darby , Nitrilos , Toluidinas/metabolismo , Toluidinas/farmacocinética , Toluidinas/farmacologíaRESUMEN
BACKGROUND: Teriflunomide is an oral disease modifying therapy approved for the treatment of relapsing forms of multiple sclerosis. Teriflunomide' s pharmacokinetics (PK) contribute to its slow elimination, on average taking 6-8 months, though it can take up to 2 years in some instances. This slow elimination can become problematic in certain clinical situations - such as during pregnancy, when teriflunomide has potential teratogenic effects. In such scenarios, an accelerated elimination procedure (AEP) is recommended. Currently, AEPs with oral cholestyramine or activated charcoal are available but are restricted by adverse effects, limited administration routes, and dosing frequencies. METHODS: A single-center, PK interaction study was performed in a total of 14 healthy volunteers, to investigate colestipol hydrochloride (HCl) as an alternative to cholestyramine for the elimination of teriflunomide. Participants received teriflunomide for 14 days, followed by an AEP with colestipol HCl for 15 days. RESULTS AND CONCLUSIONS: The administration of colestipol HCl for 15 days was sufficient to reduce plasma teriflunomide concentrations by greater than 96%. Although colestipol HCl did not completely eliminate teriflunomide with the same effectiveness as cholestyramine, it may offer an alternative method for accelerated elimination of teriflunomide with potentially improved tolerability and more favorable dosing and administration options.
Asunto(s)
Resinas de Intercambio Aniónico/farmacología , Colestipol/farmacología , Crotonatos/farmacocinética , Secuestrantes/farmacología , Toluidinas/farmacocinética , Adolescente , Adulto , Resinas de Intercambio Aniónico/administración & dosificación , Resinas de Intercambio Aniónico/efectos adversos , Resina de Colestiramina/administración & dosificación , Resina de Colestiramina/efectos adversos , Resina de Colestiramina/farmacología , Colestipol/administración & dosificación , Colestipol/efectos adversos , Crotonatos/administración & dosificación , Femenino , Humanos , Hidroxibutiratos , Masculino , Nitrilos , Secuestrantes/administración & dosificación , Secuestrantes/efectos adversos , Toluidinas/administración & dosificación , Resultado del Tratamiento , Adulto JovenRESUMEN
This study describes a comparison between LC-UV and LC-MS method for the simultaneous analyses of a few disease-modifying agents of multiple sclerosis. Quantitative determination of fampridine (FAM), teriflunomide (TFM) and dimethyl fumarate (DMF) was performed in human plasma with the recovery values in the range of 85-115%. A reversed-phase high-performance liquid chromatography (HPLC) with UV as well as MS detection is used. The method utilizes an XBridge C18 silica column and a gradient elution with mobile phase consisting of ammonium formate and acetonitrile at a flow rate of 0.5 mL min(-1) . The method adequately resolves FAM, TFM and DMF within a run time of 15 min. Owing to low molecular weights, the estimation of DMF and FAM is more versatile in UV than MS detection. With LC-UV, the detection limits of FAM, TFM and DMF were 0.1, 0.05, 0.05 µg and the quantification limit for all the analytes was 1 µg. With LC-MS, the detection and quantification limits for all of the analytes were 1 and 5 ng, respectively. The two techniques were completely validated and shown to be reproducible and sensitive. They were applied to a pharmacokinetic study in rats by a single oral dose. Copyright © 2016 John Wiley & Sons, Ltd.
Asunto(s)
4-Aminopiridina/sangre , Cromatografía Liquida/métodos , Crotonatos/sangre , Dimetilfumarato/sangre , Espectrometría de Masas/métodos , Espectrofotometría Ultravioleta/métodos , Toluidinas/sangre , 4-Aminopiridina/farmacocinética , Animales , Crotonatos/farmacocinética , Dimetilfumarato/farmacocinética , Humanos , Hidroxibutiratos , Nitrilos , Ratas , Estándares de Referencia , Reproducibilidad de los Resultados , Toluidinas/farmacocinéticaRESUMEN
AIM: Leflunomide is an immunosuppressive agent marketed as a disease-modifying antirheumatic drug. But it causes severe side effects, including fatal hepatitis and liver failure. In this study we investigated the contributions of hepatic metabolism and transport of leflunomide and its major metabolite teriflunomide to leflunomide induced hepatotoxicity in vitro and in vivo. METHODS: The metabolism and toxicity of leflunomide and teriflunomide were evaluated in primary rat hepatocytes in vitro. Hepatic cytochrome P450 reductase null (HRN) mice were used to examine the PK profiling and hepatotoxicity of leflunomide in vivo. The expression and function of sodium/bile acid cotransporter (NTCP) were assessed in rat and human hepatocytes and NTCP-transfected HEK293 cells. After Male Sprague-Dawley (SD) rats were administered teriflunomide (1,6, 12 mg · kg(-1) · d(-1), ig) for 4 weeks, their blood samples were analyzed. RESULTS: A nonspecific CYPs inhibitor aminobenzotriazole (ABT, 1 mmol/L) decreased the IC50 value of leflunomide in rat hepatocytes from 409 to 216 µmol/L, whereas another nonspecific CYPs inhibitor proadifen (SKF, 30 µmol/L) increased the cellular accumulation of leflunomide to 3.68-fold at 4 h. After oral dosing (15 mg/kg), the plasma exposure (AUC0-t) of leflunomide increased to 3-fold in HRN mice compared with wild type mice. Administration of leflunomide (25 mg·kg(-1) · d(-1)) for 7 d significantly increased serum ALT and AST levels in HRN mice; when the dose was increased to 50 mg·kg(-1) · d(-1), all HRN mice died on d 6. Teriflunomide significantly decreased the expression of NTCP in human hepatocytes, as well as the function of NTCP in rat hepatocytes and NTCP-transfected HEK293 cells. Four-week administration of teriflunomide significantly increased serum total bilirubin and direct bilirubin levels in female rats, but not in male rats. CONCLUSION: Hepatic CYPs play a critical role in detoxification process of leflunomide, whereas the major metabolite teriflunomide suppresses the expression and function of NTCP, leading to potential cholestasis.